Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

<ul>
<li>Arrail is a leading premium dental service provider in China. The company launched book building to raise up to USD 87m via a Hong Kong listing.</li>
<li>In our previous notes, we looked at the company's background, its operation, its financials, and its expansion plan, and compared its key metrics with peers and provide thoughts on valuation.</li>
<li>In this note, we provide a quick update for the book building.</li>
</ul>


Arrail is a leading premium dental service provider in China. The company launched book building to raise up to USD 87m via a Hong Kong listing.
In our previous notes, we looked at the company's background, its operation, its financials, and its expansion plan, and compared its key metrics with peers and provide thoughts on valuation.
In this note, we provide a quick update for the book building.


Arrail Group (瑞尔集团) IPO: Downsized Deal Mostly Taken by Cornerstones

<ul>
<li>Arrail is a leading dental service provider in China. The company is looking to raise up to USD100m via a Hong Kong listing.</li>
<li>In our previous note, we looked at the company's background, its operation, its financials, and its expansion plan.</li>
<li>In this note, we compare the key metric with its peer and provide our thoughts on the valuation.</li>
</ul>


Arrail is a leading dental service provider in China. The company is looking to raise up to USD100m via a Hong Kong listing.
In our previous note, we looked at the company's background, its operation, its financials, and its expansion plan.
In this note, we compare the key metric with its peer and provide our thoughts on the valuation.


Arrail Group (瑞尔集团) Pre-IPO:  Peer Comp and Thoughts on Valuation

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

The IPO of <a href="https://www.smartkarma.com/entities/angelalign-technology-inc" target="_blank" data-smartkarma-citation="entities:31480:1" rel="noopener">Angelalign Technology (6699 HK)</a> was obviously very successful, with the share price hitting an all-time high of HK$490/share in June 2021. However, in the following months, Angelalign’s share price continued to fall and was closed at HK$318.8/share on Oct. 25, down about 35%. On the other hand, Angelalign released it 2021 interim report. The revenue in 2021/1H was RMB571 million, up 85.0% YoY, and the net profit was RMB95.7 million, up 55.8% YoY, indicating good growth momentum. This insight mainly analyzed some points about the business and the concerns that worth investors’ attention.

The IPO of Angelalign Technology (6699 HK) was obviously very successful, with the share price hitting an all-time high of HK$490/share in June 2021. However, in the following months, Angelalign’s share price continued to fall and was closed at HK$318.8/share on Oct. 25, down about 35%. On the other hand, Angelalign released it 2021 interim report. The revenue in 2021/1H was RMB571 million, up 85.0% YoY, and the net profit was RMB95.7 million, up 55.8% YoY, indicating good growth momentum. This insight mainly analyzed some points about the business and the concerns that worth investors’ attention.

Angelalign Technology (6699.HK) - Some Points Worth the Attention

Aier Eye Hospital Group / Equity Bottom-Up

In August, <a href="https://www.smartkarma.com/entities/aier-eye-hospital-group-co-ltd" target="_blank" data-smartkarma-citation="entities:1103:1" rel="noopener">Aier Eye Hospital Group (300015 CH)</a> released its 2021 interim report. The revenue was RMB7.348 billion, up 76.47% YoY. Net profit attributed to shareholders was RMB1.116 billion, up 65.03% YoY. Net profit after deducting non-recurring gains and losses was RMB1.227 billion, up 111.92% YoY. The Company maintained high growth momentum. However, Aier’s share price was closed at RMB51.88/share on September 24, which was down about 28% from its all-time high of RMB72/share in February this year. This insight mainly analyzed the performance in 2021/1H and the concerns of the Company.

In August, Aier Eye Hospital Group (300015 CH) released its 2021 interim report. The revenue was RMB7.348 billion, up 76.47% YoY. Net profit attributed to shareholders was RMB1.116 billion, up 65.03% YoY. Net profit after deducting non-recurring gains and losses was RMB1.227 billion, up 111.92% YoY. The Company maintained high growth momentum. However, Aier’s share price was closed at RMB51.88/share on September 24, which was down about 28% from its all-time high of RMB72/share in February this year. This insight mainly analyzed the performance in 2021/1H and the concerns of the Company.

Aier Eye Hospital Group (300015.CH) - The Concerns Behind the High Growth Momentum

In recent years, with the steady improvement of residents' consumption level, people's attention to dental care is also increasing, which promotes the rapid development of private dental clinics in China. On July 1, 2021, <a href="https://www.smartkarma.com/entities/arrail-group-limited" target="_blank" data-smartkarma-citation="entities:33794:1" rel="noopener">Arrail Group (ARR HK)</a>, the largest premium private dental services provider in China, formally submitted its IPO prospectus to the HKEX, aiming to list on the main board. However, if look closely, Arrail is actually facing many challenges, and its outlook may not be optimistic. This insight mainly analyzed the concerns of the Company that worth the investors’ attention.

In recent years, with the steady improvement of residents' consumption level, people's attention to dental care is also increasing, which promotes the rapid development of private dental clinics in China. On July 1, 2021, Arrail Group (ARR HK), the largest premium private dental services provider in China, formally submitted its IPO prospectus to the HKEX, aiming to list on the main board. However, if look closely, Arrail is actually facing many challenges, and its outlook may not be optimistic. This insight mainly analyzed the concerns of the Company that worth the investors’ attention. 

Pre-IPO Arrail Group - The Outlook May Not Be Optimistic

China

Topchoice Medical Investment Corporation provides dental and oral health care services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Topchoice Medical (600763 CH)

Arrail Group (瑞尔集团) IPO: Downsized Deal Mostly Taken by Cornerstones

We provide a quick update for the book building for Arrail IPO. The company is a leading premium dental service provide in China seeking to raise...

Ke Yan, CFA, FRM

Arrail Group (瑞尔集团) Pre-IPO: Peer Comp and Thoughts on Valuation

We compare the key metrics of Arrail with its peer and provide our thoughts on valuation. We think the company should be valued at a discount to...

Ke Yan, CFA, FRM

Angelalign Technology (6699.HK) - Some Points Worth the Attention

This article analyzed Angelalign in terms of some points about business and concerns, such as fierce competition, product positioning,...

Xinyao (Criss) Wang

Aier Eye Hospital Group (300015.CH) - The Concerns Behind the High Growth Momentum

The article mainly analyzed Aier Eye Hospital in terms of its performance in 2021/1H and the concerns such as high acquisition premium, high...

Xinyao (Criss) Wang

Pre-IPO Arrail Group - The Outlook May Not Be Optimistic

The article mainly analyzed Arrail in terms of the concerns on margins, liquidity, talent system, valuation adjustment mechanism, expansion...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)